Literature DB >> 34749063

Synthetic mRNA - emerging new class of drug for tissue regeneration.

Elizabeth Rosado Balmayor1.   

Abstract

mRNA has the potential to be the next generation drug for tissue restoration in regenerative medicine. The variety of mRNAs that could be synthesized with the aim of increasing the expression of any required protein offers new opportunities. However, the intrinsic immunogenicity and lack of stability of mRNA has long restricted the potential of mRNA therapeutics. Fortunately, considerable progress has been made on synthetic mRNA modifications and relevant purification steps that have overcome these limitations. However, there remains a lack of efficient mRNA delivery strategies. Additionally, mRNA may need to be administered in situ via three-dimensional biomaterials. These materials, also known as transcript-activated matrices, require further consideration in terms of mRNA loading and release, immunogenicity, and other features. In this article, various limiting factors in mRNA synthesis, vector formulation, and local delivery to tissues are highlighted together with current developments and the future outlook for mRNA therapeutics in tissue regeneration.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34749063     DOI: 10.1016/j.copbio.2021.10.015

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  4 in total

1.  Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.

Authors:  Rodolfo E De La Vega; Martijn van Griensven; Wen Zhang; Michael J Coenen; Christopher V Nagelli; Joseph A Panos; Carlos J Peniche Silva; Johannes Geiger; Christian Plank; Christopher H Evans; Elizabeth R Balmayor
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

Review 2.  A brief review of mRNA therapeutics and delivery for bone tissue engineering.

Authors:  Arun Kumar Rajendran; Sivashanmugam Amirthalingam; Nathaniel S Hwang
Journal:  RSC Adv       Date:  2022-03-22       Impact factor: 3.361

Review 3.  Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids.

Authors:  Edio Maldonado; Sebastian Morales-Pison; Fabiola Urbina; Aldo Solari
Journal:  Vaccines (Basel)       Date:  2022-04-12

4.  Rapid differentiation of hiPSCs into functional oligodendrocytes using an OLIG2 synthetic modified messenger RNA.

Authors:  Jian Xu; Zhihua Yang; Rui Wang; Fumei He; Rong Yan; Yidi Zhang; Liying Yu; Wenbin Deng; Yichu Nie
Journal:  Commun Biol       Date:  2022-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.